SecBot SecBot
SECBOTREPLAY Home › Report › SLNO

SLNO · Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per…

SOLENO THERAPEUTICS INC · 8-K filed Apr 6, 2026 at 07:46 ET

At the news

BULLISHIMPACT 8/10

8-K filed Apr 6, 2026 at 07:46 ET

Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash, representing a total equity value of $2.9 billion. The acquisition includes Soleno's FDA-approved treatment VYKATTM XR for Prader-Willi syndrome, which generated $190 million in 2025 revenue. The deal is expected to close within 90 days, subject to regulatory approvals and other customary conditions.

  • Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash
  • Total transaction equity value is $2.9 billion
  • VYKATTM XR generated $190 million in 2025 revenue, including $92 million in Q4 2025
  • The deal represents a 34% premium to Soleno's closing price on April 2, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access